Manufacturing News of Note—Aurobindo gets 2 483s; Catalent to make BeiGene drug

stocks
(Pixabay)

> The FDA recently posted two Form 483s issued to India’s Aurobindo in October; one for a sterile facility and one for an API facility. 

> CDMO Catalent has been tapped by China's BeiGene, to manufacture its immuno-oncology drug Brukinsa. Release 

> South Korea and Singapore have signed an agreement to work together and share information GMP inspections. Story 

> Ingredient supplier Barentz says that private equity firm Cinven has made an investment that will allow it to expand. Story 

Suggested Articles

Sanofi will unload six manufacturing sites and 3,100 employees into a new API production company as it looks for €2 billion in cost savings.

With a new target date approaching for its competitor to Lantus, the FDA has again given Biocon’s insulin manufacturing plant in Malaysia a once over.

Colorado is making a play for a Japanese CDMO in hopes it will invest about $100 million in an empty AstraZeneca plant in Boulder.